title: Influence of mildronat on left ventricular systolic, diastolic functional parameters, pulmonary arterial flow and systolic dyssynchrony in patients with congestive heart failure.
abstract: The aim of the study was to investigate the influence of metabolic treatment with Mildronat on left and right ventricular function, pulmonary flow and systolic synchrony in patient with heart failure. We studied 16 persons with 2-3-d NYHA class Heart Failure, 8 male and 8 female (age 69.2±9.3). All where in stable condition at last for 3 months and take traditional medical treatment (ACE inhibitors or AT2-blockers, beta-blockers, Furosemide, Spirolactone). It was added Mildronat (500 mg 2x daily per os) for 2 months. All patient undergone standard EchoCG, PW and Color Tissue Doppler (TD) examination before and after 2 months of treatment with Mildronat. It was noted significant decrease LV end systolic volume and increase of Ejection Fraction and Fractional Shortening of LV after 2 month treatment with Mildronat. LV Tissue Doppler parameters did not change significantly, it was noted only tendency of increasing Right Ventricular systolic velocity. Pulmonary Arterial Acceleration Time significantly increased, right ventricular (RV) isovolumic relaxation time and RV TEI index (Systolic-Diastolic Index) on Tissue Doppler was significantly decreased after the treatment, which indicates improvement of RV function and decrease of Pulmonary Arterial Pressure. There was improvement of Intraventricular synchrony, systolic delay time between intraventricular septum and lateral wall became shorter after 2 month treatment with Mildronat but interventricular delay did not change significantly. Addition of Mildronat to traditional medical treatment improves left ventricular systolic function in patients with Heart Failure. Mildronat improves left ventricular systolic dissynchroni in patients with Heart Failure. Mildronat increases the pulmonary arterial flow acceleration time and shortens Right Ventricular isovolumic relaxation time and TEI index, this means that it reduces the Pulmonary Arterial Pressure and improves right ventricular function.
authors.forename: M D
authors.initials: MD
authors.lastname: Tsverava
mesh_terms: D000368:Aged; D015150:Echocardiography, Doppler; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008763:Methylhydrazines / Q000008:administration & dosage*; D008875:Middle Aged; D011651:Pulmonary Artery / Q000187:drug effects / Q000473:pathology; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D008763:Methylhydrazines; C050147:3-(2,2,2-trimethylhydrazine)propionate